Long-term Study of KAD-1229 in Type 2 Diabetes Patients

• Status: Completed
• Trial end date: 2012-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the long-term safety and efficacy of KAD-1229 as combination therapy with biguanide or DPP-4 inhibitor in type 2 diabetes patients who show inadequate glycemic control with diet, and biguanide or DPP-4 inhibitor monotherapy.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kissei Pharmaceutical Co., Ltd.
• Treatments: Mitiglinide

Criteria

Inclusion Criteria:

• Type 2 diabetes patients who show inadequate glycemic control with diet, and biguanide or DPP-4 inhibitor monotherapy

• Age in the 20 years or over inclusive

• HbA1c in the range of ≥ 6.5 to < 9%

Exclusion Criteria:

• Type 1 diabetes mellitus

• Patients with serious diabetic complications and other serious complications